Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab + Chemo in Gastric/GEJ Cancer
NCT03662659Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 17
01
Overview
A Phase 2 trial of relatlimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Bristol Myers Squibb. Started Oct 2018; status: completed.
02
Drugs
relatlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03662659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662659.